Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

• Published in: Journal of clinical oncology Vol. 19; no. 13; pp. 3267 - 3279
• Main Authors: HIDALGO, Manuel, SIU, Lillian L, FERRANTE, Karen, VON HOFF, Daniel D, SILBERMAN, Sandra, ROWINSKY, Eric K, NEMUNAITIS, John, RIZZO, Jinee, HAMMOND, Lisa A, TAKIMOTO, Chris, ECKHARDT, S. Gail, TOLCHER, Anthony, BRITTEN, Carolyn D, DENIS, Louis
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 01.07.2001; Lippincott Williams & Wilkins
• Subjects: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Biological and medical sciences; Biological Availability; Chemotherapy; Diarrhea - chemically induced; Dose-Response Relationship, Drug; Drug Eruptions - etiology; Female; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Medical sciences; Middle Aged; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Pharmacology. Drug treatments; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Statistics, Nonparametric; Antineoplastic agent; Human; Enzyme; Maximal dose; Toxicity; Transferases; Quinazoline derivatives; Cytokine; Enzyme inhibitor; Malignant tumor; Chemotherapy; Growth factor receptor; Epidermal growth factor; Treatment; Polypeptide; Phase I trial; Complication; Advanced stage; Pharmacokinetics; Protein-tyrosine kinase; Growth factor
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2001.19.13.3267

To assess the feasibility of administering OSI-774, to recommend a dose on a protracted, continuous daily schedule, to characterize its pharmacokinetic behavior, and to acquire preliminary evidence of anticancer activity. Patients with advanced solid malignancies were treated with escalating doses of OSI-774 in three study parts (A to C) to evaluate progressively longer treatment intervals. Part A patients received OSI-774 25 to 100 mg once daily, for 3 days each week, for 3 weeks every 4 weeks. Part B patients received OSI-774 doses ranging from 50 to 200 mg given once daily for 3 weeks every 4 weeks to establish the maximum tolerated dose (MTD). In part C, patients received this MTD on a continuous, uninterrupted schedule. The pharmacokinetics of OSI-774 and its O-demethylated metabolite, OSI-420, were characterized. Forty patients received a total of 123 28-day courses of OSI-774. No severe toxicities precluded dose escalation of OSI-774 from 25 to 100 mg/d in part A. In part B, the incidence of severe diarrhea and/or cutaneous toxicity was unacceptably high at OSI-774 doses exceeding 150 mg/d. Uninterrupted, daily administration of OSI-774 150 mg/d represented the MTD on a protracted daily schedule. The pharmacokinetics of OSI-774 were dose independent; repetitive daily treatment did not result in drug accumulation (at 150 mg/d [average]: minimum steady-state plasma concentration, 1.20 +/- 0.62 microg/mL; clearance rate, 6.33 +/- 6.41 L/h; elimination half-life, 24.4 +/- 14.6 hours; volume of distribution, 136. 4 +/- 93.1 L; area under the plasma concentration-time curve for OSI-420 relative to OSI-774, 0.12 +/- 0.12 microg/h/mL). The recommended dose for disease-directed studies of OSI-774 administered orally on a daily, continuous, uninterrupted schedule is 150 mg/d. OSI-774 was well tolerated, and several patients with epidermoid malignancies demonstrated either antitumor activity or relatively long periods of stable disease. The precise contribution of OSI-774 to these effects is not known.